Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

February 25, 2009

Last Updated Date

February 25, 2009

Start Date ^†

May 2007

Current Primary Outcome Measures ^†

All cause mortality [ Time Frame: One year ] [ Designated as safety issue: No ]

Original Primary Outcome Measures ^†

Same as current

Change History

No Changes Posted

Current Secondary Outcome Measures ^†

For pancreatic patients from whom tissue samples will be available, we will examine the association between presence/absence of each marker in the tissue versus the marker level in blood and in pancreatic juice. [ Time Frame: One year ] [ Designated as safety issue: No ]

Original Secondary Outcome Measures ^†

Same as current

Descriptive Information

Brief Title ^†

Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer

Official Title ^†

Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer

Brief Summary

The investigators hypothesize that the CXCR2 ligands/CXCR2 biological axis plays an important role in promoting angiogenesis in PC; and that the genetic changes and the microenvironment of the tumor regulate the expression of CXCR2 ligands/CXCR2 in PC in order to potentiate their angiogenic phenotype. A corollary of this hypothesis is that the cell surface receptors (CXCR2) and the intracellular signaling pathways that mediate the angiogenic responses induced by ELR+ CXC-chemokines are potential targets for novel therapeutic interventions in PC.

Detailed Description

Study Phase

Study Type ^†

Observational

Study Design ^†

Case-Only, Prospective

Condition ^†

Chronic Pancreatitis
Pancreatic Cancer

Intervention ^†

Study Arms / Comparison Groups

Patients with no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test (EUS, CT scan or MRI).
Patients with documented diagnosis of moderate to advanced chronic pancreatitis supported by at least 1 positive imaging test (EUS,CT scan or MRI).
Patients with documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Recruiting

Enrollment ^†

150

Completion Date

Primary Completion Date

Eligibility Criteria ^†

Inclusion Criteria:

Normal subjects - No documented clinical history of pancreatic diseases supported by at least 1 negative imaging test. (EUS, Ct scan or MRI)
Chronic pancreatitis - Documented diagnosis of moderate to advanced chronic supported bpancreatitisy at least 1 positive imaging test. (EUS, Ct scan or MRI)
Pancreatic Cancer - Documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.

Exclusion Criteria:

Exclusion criteria will include age younger than 18 yrs, pregnancy, previous pancreatic or gastric resection, and inability to tolerate routine endoscopy with conscious sedation

Gender

Both

Ages

18 Years to 90 Years

Accepts Healthy Volunteers

Yes

Contacts ^††

Contact: Massimo Raimondo, MD	904-953-2000	Raimondo.massimo@mayo.edu
Contact: Verna A. Skinner, CCRP	904-953-8982	skinner.verna@mayo.edu

Location Countries ^†

United States

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00851955

Responsible Party

ChiRhonClin, ChiRhoClin, Inc.

Secondary IDs ^††

Study Sponsor ^†

Mayo Clinic

Collaborators ^††

Investigators ^†

Principal Investigator:

Massimo Raimondo, MD

Mayo Clinic

Information Provided By

Mayo Clinic

Verification Date

February 2009

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.